Haematologica (Mar 2025)

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation

  • Iryna Lastovytska,
  • Silke Heidenreich,
  • Evgeny Klyuchnikov,
  • Christian Niederwieser,
  • Nico Gagelmann,
  • Johanna Richter,
  • Radwan Massoud,
  • Kristin Rathje,
  • Tetiana Perekhrestenko,
  • Gaby Zeck,
  • Catherina Lück,
  • Dietlinde Janson,
  • Christine Wolschke,
  • Francis Ayuk,
  • Nicolaus Kröger

DOI
https://doi.org/10.3324/haematol.2024.286824
Journal volume & issue
Vol. 999, no. 1

Abstract

Read online

We compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo, n=29) or Ruxo plus extracorporeal photopheresis (Ruxo-ECP, n=49). Patients were well balanced between both arms except for SR-aGVHD grade IV which was higher in the Ruxo-ECP group (45% vs. 14%, p